Rigel Pharmaceuticals, Inc.

RIGL ·Healthcare, Drug Manufacturers - General, United States

Net Cash Flow Breakdown

FY2025 FY2024 FY2021 FY2010

Total Cash from Operations: $382.8M

Line Item	Value	% of Total
Other Investing	$76.3M	19.9%
Working Capital	$306.5M	80.1%